Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc (NQ: BEAM )

24.30 +0.29 (+1.19%)
Streaming Delayed Price Updated: 10:34 AM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Beam Therapeutics Inc

< Previous 1 2 3 4 5 6 Next >
Beyond Meat, Canoo, Veru And More: 12 Short Squeeze Candidates To Watch
One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky has just released a... 
Via Benzinga
Why Did BMO Capital Markets Raise Price Target For Gene Stock One Month After Initiating Coverage
Via Benzinga
The Next CRISPR Is Here: How Verve Plans To Rival Amgen, Regeneron In Cholesterol
This could offer an improvement over CRISPR, which requires cutting DNA. 
Via Investor's Business Daily
The 3 Leaders of the Gene Editing Revolution
There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch. 
Via InvestorPlace
7 Moonshot Investments Upending a $10 Trillion Industry
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. 
Via InvestorPlace
BMO Capital Says Risk/Reward For This Gene Stock Assumes Clinical Success
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
During Friday's morning session, 234 stocks hit new 52-week lows. Interesting Facts About Today's 52-Week Lows: The largest company in terms of market cap... 
Via Benzinga
Expert Ratings For Beam Therapeutics
Within the last quarter, Beam Therapeutics (NASDAQ:BEAM) has observed the f... 
Via Benzinga
Verve Therapeutics Amends Gene Editing Pact With Beam Therapeutics
Verve Therapeutics Inc (NASDAQ: VERV) entered into an amended and restated collaboration and license Agreement with Beam Therapeutics Inc (NASDAQ: 
Via Benzinga
Is Pfizer Stock A Buy Or A Sell As Its Covid Vaccine Faces A New Lawsuit?
The FDA's advisors recently backed Pfizer's Covid shot for young children. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new... 
Via Benzinga
Stock Market Rebound Fizzles Amid Hawkish Fed; Taiwan Semiconductor Breaks Out, JPMorgan Tumbles: Weekly Review
A rebound from Monday's lows faded, with the key indexes all down for the week. 
Via Investor's Business Daily
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks
Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year? 
Via Investor's Business Daily
Pfizer Continues Its Covid Makeover: What's Next For This Hot Stock?
How the pandemic continued a transformation Pfizer says began years ago. 
Via Investor's Business Daily
Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer
Pfizer and Bayer inked deals with several companies in gene-editing. 
Via Investor's Business Daily
Pfizer, Beam Ink Multi-Target Research Collaboration For In Vivo Base Editing Programs
Pfizer Inc (NYSE: PFE) and Beam Therapeutics Inc (NASDAQ: BEAM) have announced an exclusive four-year research collaboration focused on in vivo ... 
Via Benzinga
Pfizer Makes Foray Into CRISPR, Inking $1.35 Billion Deal With Beam Therapeutics
The companies hope to cure diseases of the liver, muscle and central nervous system. 
Via Investor's Business Daily
Top 5 Moonshots for 2022 Countdown: My No. 5 Pick
2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year. 
Via InvestorPlace
Got $1,000? Check Out These 3 Top Biotech Stocks
Two big biotechs and one smaller one that could be winners over the long term. 
Via The Motley Fool
Being First Is Not Enough For Crispr Therapeutics
CRSP stock is facing competition and meeting skepticism as the company tries to turn CRISPR-CAS9 into profitable drug therapies. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2022
Upgrades According to TD Securities, the prior rating for Canada Goose Holdings Inc (NYSE: 
Via Benzinga
In Conversation: CMC Markets and ARK Investment Management on the Future of Genomic Testing
Photo by cottonbro from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner... 
Via Benzinga
Cathie Wood's Buying Beam Therapeutics -- Should You?
Can this high-flying gene-editing stock keep on climbing for new investors? 
Via The Motley Fool
Looking Into Beam Therapeutics's Return On Capital Employed
Beam Therapeutics (NASDAQ:BEAM) brought in sales totaling $763.00 thousand during Q3 according to data provided by Benzinga Pro. However, earnings decreased 18.08%, resulting in a... 
Via Benzinga
Sana Obtains License To Beam Therapeutics' CRISPR Cas12b Gene Editing Technology
Sana Biotechnology Inc (NASDAQ: SANA) has secured non-exclusive commercial rights to Beam Therapeutics Inc's (NASDAQ: BEAM) CRISPR Cas12b nuclease... 
Via Benzinga
Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week
A key gene-editing readout had Cathie Wood shuffling her portfolio. 
Via The Motley Fool
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021
Upgrades Maxim Group upgraded the previous rating for Indaptus Therapeutics Inc (NASDAQ: 
Via Benzinga
Beam Therapeutics Stock Flashes Renewed Technical Strength
On Tuesday, Beam Therapeutics stock reached an key performance benchmark, seeing its RS Rating jump to 92, up from 88 the day before. 
Via Investor's Business Daily
Beam Therapeutics' Base Editors Show Encouraging Preclinical Action In HBV Infection
Beam Therapeutics Inc (NASDAQ: BEAM) has announced preclinical data for its cytosine base editors (CBEs). The data demonstrate the potential of CBEs to reduce... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.